MCL Literature Feed
25 papers on mantle cell lymphoma from PubMed. Updated daily.
A case report demonstrates that MCL can relapse in rare sites like skeletal muscle after rituximab maintenance, underscoring the value of PET/CT for detecting atypical disease progression.
Frontline zanubrutinib-rituximab induction achieved an 88% complete response rate, enabling a shortened R-DHAOx consolidation, offering a highly effective, chemotherapy-de-escalation strategy for newly diagnosed MCL.
Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.
This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.
Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.
Real-world data from older Chinese MCL patients shows BTKi-based regimens and maintenance therapy significantly improve survival, validating these strategies for this specific, understudied elderly population.
This case report identifies chronic enteroviral meningoencephalitis as a severe neurotoxicity of rituximab maintenance in MCL, demonstrating successful resolution with intravenous immunoglobulins (IVIg) and fluoxetine.
This review advocates for integrating BTK inhibitors into frontline MCL therapy for all patients, particularly for TP53-mutated disease, challenging the standard role of chemotherapy.
This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.
The Japanese Society of Hematology's 2023 guidelines provide updated, evidence-based recommendations on risk stratification and treatment algorithms for managing mantle cell lymphoma in clinical practice.
This study compares bendamustine-rituximab (BR) versus R-CHOP as initial therapy for transplant-ineligible MCL patients, providing evidence to guide frontline treatment selection in this common clinical setting.
This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.
In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.
Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.
In older, frontline MCL patients, adding bortezomib to BR induction or lenalidomide to rituximab maintenance did not improve PFS, confirming BR-R as a highly effective standard.
For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.
This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This multicenter retrospective study analyzes real-world maintenance strategies in mantle cell lymphoma, providing evidence to guide treatment selection and duration after initial therapy.
This meta-analysis across B-NHLs confirms lenalidomide-based regimens improve OS and PFS, supporting its established role in relapsed/refractory and maintenance settings for MCL.
Long-term follow-up confirms rituximab maintenance post-transplant significantly improves overall survival in young, fit MCL patients, establishing this as a standard of care in the frontline setting.
This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.
In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.